SG11202100700VA - Immune modifying particles for the treatment of cancer - Google Patents
Immune modifying particles for the treatment of cancerInfo
- Publication number
- SG11202100700VA SG11202100700VA SG11202100700VA SG11202100700VA SG11202100700VA SG 11202100700V A SG11202100700V A SG 11202100700VA SG 11202100700V A SG11202100700V A SG 11202100700VA SG 11202100700V A SG11202100700V A SG 11202100700VA SG 11202100700V A SG11202100700V A SG 11202100700VA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- modifying particles
- immune modifying
- immune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862712604P | 2018-07-31 | 2018-07-31 | |
| US201962788569P | 2019-01-04 | 2019-01-04 | |
| PCT/US2019/044454 WO2020028544A1 (en) | 2018-07-31 | 2019-07-31 | Immune modifying particles for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100700VA true SG11202100700VA (en) | 2021-02-25 |
Family
ID=69230909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100700VA SG11202100700VA (en) | 2018-07-31 | 2019-07-31 | Immune modifying particles for the treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3829548A4 (en) |
| JP (1) | JP2021532136A (en) |
| KR (1) | KR20210053891A (en) |
| CN (1) | CN112823001A (en) |
| AU (1) | AU2019312589A1 (en) |
| BR (1) | BR112021001858A2 (en) |
| CA (1) | CA3107134A1 (en) |
| IL (1) | IL280468A (en) |
| MX (1) | MX2021001252A (en) |
| SG (1) | SG11202100700VA (en) |
| WO (1) | WO2020028544A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114502557A (en) * | 2019-07-31 | 2022-05-13 | onCOUR制药股份有限公司 | Treatment of immune-evasive tumors |
| CN112410302B (en) * | 2020-11-10 | 2023-02-17 | 福建医科大学 | Multi-target combination based tumor stem cell enrichment and screening method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8043631B2 (en) * | 2004-04-02 | 2011-10-25 | Au Jessie L S | Tumor targeting drug-loaded particles |
| IL292823B2 (en) * | 2013-03-13 | 2023-11-01 | Cour Pharmaceuticals Dev Company | Immune-modifying particles for the treatment of inflammation |
-
2019
- 2019-07-31 CN CN201980056725.3A patent/CN112823001A/en active Pending
- 2019-07-31 BR BR112021001858-1A patent/BR112021001858A2/en unknown
- 2019-07-31 MX MX2021001252A patent/MX2021001252A/en unknown
- 2019-07-31 JP JP2021504155A patent/JP2021532136A/en active Pending
- 2019-07-31 KR KR1020217006018A patent/KR20210053891A/en unknown
- 2019-07-31 AU AU2019312589A patent/AU2019312589A1/en active Pending
- 2019-07-31 SG SG11202100700VA patent/SG11202100700VA/en unknown
- 2019-07-31 WO PCT/US2019/044454 patent/WO2020028544A1/en active Application Filing
- 2019-07-31 CA CA3107134A patent/CA3107134A1/en active Pending
- 2019-07-31 EP EP19844270.9A patent/EP3829548A4/en active Pending
-
2021
- 2021-01-28 IL IL280468A patent/IL280468A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021532136A (en) | 2021-11-25 |
| WO2020028544A1 (en) | 2020-02-06 |
| KR20210053891A (en) | 2021-05-12 |
| EP3829548A4 (en) | 2022-05-04 |
| BR112021001858A2 (en) | 2021-05-04 |
| IL280468A (en) | 2021-03-01 |
| CA3107134A1 (en) | 2020-02-06 |
| CN112823001A (en) | 2021-05-18 |
| MX2021001252A (en) | 2021-05-27 |
| EP3829548A1 (en) | 2021-06-09 |
| AU2019312589A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264674B1 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| IL267795A (en) | Combination therapy for the treatment of cancer | |
| EP3641829A4 (en) | Interferon prodrug for the treatment of cancer | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| IL274766A (en) | Humanized anti-liv1 antibodies for the treatment of breast cancer | |
| IL263793A (en) | Compounds and compositions for the treatment of cancer | |
| SG11202011117VA (en) | Treatment of cancer | |
| IL290130A (en) | Treatment of immune evasive tumors | |
| IL269357A (en) | Combination therapies for the treatment of breast cancer | |
| IL281845A (en) | Combination therapy for the treatment of cancer | |
| IL285807A (en) | Immunotherapy for the treatment of cancer | |
| ZA201808232B (en) | Compositions and methods for the treatment of cancer | |
| IL279609A (en) | Bifunctional compositions for the treatment of cancer | |
| IL284162A (en) | Combination therapy for the treatment of cancer | |
| IL280468A (en) | Immune modifying particles for the treatment of cancer | |
| IL266993A (en) | Combination therapy for the treatment of cancer | |
| SG11201805434UA (en) | Bacterial ghosts for the treatment of cancer | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| IL272147A (en) | Methods and compositions for the treatment of cancer | |
| IL282313A (en) | Abituzumab for the treatment of colorectal cancer | |
| IL280262A (en) | Compositions and methods for the treatment of cancer | |
| IL275981A (en) | Combination therapies for the treatment of breast cancer | |
| IL273835A (en) | Combination product for the treatment of cancer | |
| GB201816547D0 (en) | Oncolytic virus for the treatment of cancer | |
| PL3630754T3 (en) | Isoindoline-acetylene compounds for the treatment of cancer |